865466-24-6

• 常用中文名：那拉匹韦
• 常用英文名：Narlaprevir
• CAS号：865466-24-6
• 分子式：C₃₆H₆₁N₅O₇S
• 分子量：707.964
• 相关类别： 信号通路 抗感染 HCV
• 发布时间：2018-12-21 15:42:22
• 更新时间：2026-07-07 20:08:12
• Narlaprevir是口服生物相容性的NS3蛋白酶抑制剂,Ki为6 nM,EC90为40 nM。

名称

• 中文名: (2S)-2-((4-(((2,7-二甲基-4-氧代-1,4-二氢喹唑啉-6-基)甲基)(丙-2-炔基)氨基)-2-氟苯甲酰)氨基)-4-(1H-四唑-5-基)丁酸
• 英文名: (1R,2S,5S)-3-[(2S)-2-[[1-(tert-butylsulfonylmethyl)cyclohexyl]carbamoylamino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxoheptan-3-yl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
• 中文别名: (1R,2S,5S)-N-[(1S)-1-[(CYCLOPROPYLAMINO)OXOACETYL]PENTYL]-3-[(2S)-2-[[[[1-[[(1,1-DIMETHYLETHYL)SULFONYL]METHYL]CYCLOHEXYL]AMINO]CBONYL]AMINO]-3,3-DIMETHYL-1-OXOBUTYL]-6,6-DIMETHYL-3-AZABICYCLO[3.1.0]HEXANE-2-CBOXAMIDE 无结构图; (1R,2S,5S)-N-[(1S)-1-[(环丙基氨基)氧代乙酰基]戊基]-3-[(2S)-2-[[[[1-[[(叔丁基)磺酰]甲基]环己基]氨基]羰基]氨基]-3,3-二甲基-1-氧代丁基]-6,6-二甲基-3-氮杂双环[3.1.0]己烷-2-甲酰胺; 那拉匹韦-[D5]/精确称量
• 英文别名: (1R,2S,5S)-3-((S)-2-(3-(1-(tert-butylsulfonylmethyl)cyclohexyl)ureido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxoheptan-3-yl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide; 3-Azabicyclo[3.1.0]hexane-2-cboxamide, N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]pentyl]-3-[(2S)-2-[[[[1-[[(1,1-dimethylethyl)sulfonyl]methyl]cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-, (1R,2S,5S); (1R,2S,5S)-N-[(1S)-1-[(Cyclopropylamino)oxoacetyl]pentyl]-3-[(2S)-2-[[[[1-[[(1,1-dimethylethyl)sulfonyl]methyl]cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-cboxamide; SCH 900518;SCH900518;SCH-900518; Nlaprevir; (1R,2S,5S)-N-[(3S)-1-(Cyclopropylamino)-1,2-dioxo-3-heptanyl]-6,6-dimethyl-3-{3-methyl-N-[(1-{[(2-methyl-2-propanyl)sulfonyl]methyl}cyclohexyl)carbamoyl]-L-valyl}-3-azabicyclo[3.1.0]hexane-2-carboxamide; CS-0445; Narlaprevir (USAN/INN); Sch; Sch 900518 Nlaprevir; (1R,5S)-N-[1(S)-[2-(cyclopropylamino)-1,2-dioxoethyl]pentyl]-3-[2(S)-[[[[1-[[(1,1-dimethylethyl)sulfonyl]methyl]cyclohexyl]amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide

物化性质

• 密度: 1.2±0.1 g/cm3
• 分子式: C₃₆H₆₁N₅O₇S
• 分子量: 707.964
• 精确质量: 707.429199
• PSA: 186.21000
• LogP: 3.61
• 折射率: 1.558
• 储存条件: -20°C，密闭，干燥

生物活性

• 描述: Narlaprevir是口服生物相容性的NS3蛋白酶抑制剂,Ki为6 nM,EC90为40 nM。
• 相关类别:
  信号通路 >> 代谢酶/蛋白酶 >> HCV蛋白酶
  信号通路 >> 抗感染 >> HCV
  研究领域 >> 感染
• 参考文献:

  [1]. Ashok Arasappan, et al. Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor. ACS Med. Chem. Lett., 2010, 1 (2), pp 64–69

  [2]. Tong X, Arasappan A, Bennett F, Chase R, Feld B, Guo Z, Hart A, Madison V, Malcolm B, Pichardo J, Prongay A, Ralston R, Skelton A, Xia E, Zhang R, Njoroge FG.Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.Antimicrob Agents Chemother. 2010 Jun;54(6):2365-70. Epub 2010 Mar 22.

  [3]. Zhu J, Li Y, Yu H, Zhang L, Mao X, Hou T.Insight into the structural requirements of narlaprevir-type inhibitors of NS3/NS4A protease based on HQSAR and molecular field analyses.Comb Chem High Throughput Screen. 2012 Jul;15(6):439-50.

  [4]. de Bruijne J, Bergmann JF, Reesink HW, Weegink CJ, Molenkamp R, Schinkel J, Tong X, Li J, Treitel MA, Hughes EA, van Lier JJ, van Vliet AA, Janssen HL, de Knegt RJ.Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients.Hepatology. 2010 Nov;52(5):1590-9.

  [5]. Tomillero A, Moral MA.Gateways to clinical trials.Methods Find Exp Clin Pharmacol. 2010 Nov;32(9):675-703.

合成路线

上下游产品

上游产品  8
110-62-3 4630-82-4 18999-28-5 40195-26-4
254438-52-3 1184928-27-5 1208245-90-2 108-94-1
下游产品  0